Vimarsana
Biggest News Aggregation in the World

Page 3 - Nat Microbiol News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Nat Microbiol. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Nat Microbiol Today - Breaking & Trending Today

Promising New Drug May Effectively Treat Chagas Disease - Vimarsana News

Promising New Drug May Effectively Treat Chagas Disease

After more than 50 years, researchers have discovered a potential treatment for Chagas disease that has shown promise in non-human primate trials.

Investegate |AstraZeneca PLC Announcements | AstraZeneca PLC: Evusheld approved for COVID-19 in Japan - Vimarsana News

Investegate |AstraZeneca PLC Announcements | AstraZeneca PLC: Evusheld approved for COVID-19 in Japan

Investegate announcements from AstraZeneca PLC, Evusheld approved for COVID-19 in Japan

Anatomy of a 'correlate of protection' for T-cell vaccines - Vimarsana News

Anatomy of a 'correlate of protection' for T-cell vaccines

Here, Thomas Rademacher of Emergex Vaccines explains how delivery of virus-specific major MHC class I epitopes to the skin-resident immune system can translate to the presence of antigen-specific memory T-cells at distal sites.

Breaking down the role of the gut microbiome - Vimarsana News

Breaking down the role of the gut microbiome

BioPharma

Evusheld significantly prevented COVID-19 disease progression or death in TACKLE Phase III treatment trial - Vimarsana News

Evusheld significantly prevented COVID-19 disease progression or death in TACKLE Phase III treatment trial

Detailed results from the TACKLE Phase III outpatient treatment trial showed AstraZeneca’s Evusheld (tixagevimab and cilgavimab, formerly AZD7442) provided clinically and statistically significant protection against progression to severe COVID-19 or death from any cause compared to placebo, with treatment with ...